D P Vaughan, R Fumi, M Theilmann Jensen, T Georgiades, L Wu, D Lux, R Obrocki, J Lamoureux, O Ansorge, Ksj Allinson, T T Warner, Z Jaunmuktane, A Misbahuddin, P N Leigh, Bcp Ghosh, K P Bhatia, A Church, C Kobylecki, Mtm Hu, J B Rowe, C Blauwendraat, H R Morris, E Jabbari
BACKGROUND: Seed amplification assay (SAA) testing has become an important biomarker in the diagnosis of alpha-synuclein related neurodegenerative disorders. OBJECTIVES: To assess the rate of alpha-synuclein SAA positivity in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), and analyse the clinical and pathological features of SAA positive and negative cases. METHODS: 106 CSF samples from clinically diagnosed PSP (n=59), CBS (n=37) and indeterminate parkinsonism cases (n=10) were analysed using alpha-synuclein SAA...
February 29, 2024: medRxiv